


# PREVALENCE of Cancer of the PROSTATE in SWITZERLAND

Figure 1. Observed and projected number of patients having been diagnosed with malignant cancer of the prostate by index year and years since diagnosis.



**Table 1. Malignant cancer of the prostate (ICD-10 C61).  
Limited-duration prevalence in Switzerland by sex, age and year.**

		Limited-duration prevalence <sup>2</sup>															
		Men								Women							
		2000		2005		2010		2015		2000		2005		2010		2015	
Age <sup>3</sup>	Time since diagnosis [years]	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>
0-49	up to 2	30	1	69	3	136	5	84	3								
	up to 5	43	2	116	5	250	10	185	7								
	up to 10	49	2	121	5	330	13	269	10								
	2 to 5	13	1	48	2	114	4	101	4								
	5 to 10	6	0	4	0	80	3	84	3								
50-59	up to 2	826	176	1225	251	1295	244	1257	208								
	up to 5	1250	267	2160	442	2408	453	2323	384								
	up to 10	1362	291	2443	500	2914	549	2903	480								
	2 to 5	424	91	936	192	1113	210	1066	176								
	5 to 10	111	24	282	58	506	95	579	96								
60-69	up to 2	2632	833	4055	1117	4544	1085	4847	1088								
	up to 5	4824	1527	8333	2296	9792	2339	10235	2297								
	up to 10	5864	1857	10678	2942	14541	3473	16002	3592								
	2 to 5	2192	694	4278	1179	5248	1254	5387	1209								
	5 to 10	1041	330	2345	646	4749	1134	5768	1295								
70-79	up to 2	3282	1563	3851	1689	3715	1482	4411	1507								
	up to 5	7069	3368	9423	4133	9218	3676	10391	3550								
	up to 10	10238	4878	14658	6430	17340	6916	19453	6646								
	2 to 5	3787	1804	5572	2444	5503	2195	5981	2043								
	5 to 10	3170	1510	5236	2297	8123	3240	9061	3096								
80+	up to 2	1459	1515	1596	1409	1423	1083	1829	1205								
	up to 5	3522	3659	3800	3355	3567	2717	4247	2799								
	up to 10	5990	6223	7144	6307	7644	5822	8242	5431								
	2 to 5	2064	2144	2204	1946	2144	1633	2418	1594								
	5 to 10	2467	2563	3344	2952	4078	3106	3995	2633								
All ages	up to 2	8229	234	10795	295	11112	287	12428	305								
	up to 5	16708	475	23832	652	25234	651	27381	672								
	up to 10	23503	668	35043	959	42770	1104	46868	1151								
	2 to 5	8479	241	13037	357	14122	364	14953	367								
	5 to 10	6795	193	11211	307	17536	452	19487	478								

<sup>1</sup> Proportion per 100'000

<sup>2</sup> Estimated with Counting/Projection-Method (see chapter B and C in document "Prevalence estimation methods")

<sup>3</sup> Age at index date

**Table 2. Malignant cancer of the prostate (ICD-10 C61).  
Complete prevalence in Switzerland by sex and year.**

		Complete prevalence <sup>2</sup>															
		Men								Women							
		2000		2005		2010		2015		2000		2005		2010		2015	
Age <sup>3</sup>	Time since diagnosis [years]	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>	N	Prop <sup>1</sup>
All ages	more than 10	2390	68	4330	119	7735	200	13331	327								
	unlimited <sup>4</sup>	25894	736	39373	1078	50505	1303	60198	1478								

<sup>1</sup> Proportion per 100'000

<sup>2</sup> Estimated with Age-Period-Cohort model PIAMOD (see chapter D in document "Prevalence estimation methods")

<sup>3</sup> Age at index date

<sup>4</sup> Modelled prevalence is potentially underestimated as compared with counted prevalence in Tab. 1. The modelled 5-year limited duration prevalence for 2000 - 2010 was 12% smaller on average (see chapter D 4.2. in document "Prevalence estimation methods"). The complete prevalence was estimated by taking the sum of counted limited duration prevalences (0-2, 2-5, 5-10) and the modelled 10+ years prevalence.

May 2014

Contact: Matthias Lorez, PhD MAS  
Foundation National Institute for Cancer Epidemiology and Registration (NICER)  
c/o Universität Zürich  
Seilergraben 49  
CH-8001 Zürich  
ml@nicer.org